Aurinia Pharmaceuticals Inc (AUPH) News

Aurinia Pharmaceuticals Inc (AUPH): $9.21

0.16 (+1.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter AUPH News Items

AUPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AUPH News Highlights

  • AUPH's 30 day story count now stands at 9.
  • Over the past 22 days, AUPH's stories per day has been in a clear downtrend, falling by about 0.26 per 2 days.
  • The most mentioned tickers in articles about AUPH are ROAD, ROSE and SUN.

Latest AUPH News From Around the Web

Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.

Aurinia Announces PTAB Has Terminated Inter Partes Review

VICTORIA, British Columbia, January 25, 2023--Aurinia Announces PTAB Has Terminated Inter Partes Review

Yahoo | January 25, 2023

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

VICTORIA, British Columbia, January 24, 2023--AURINIA PHARMACEUTICALS ANNOUNCES ALLOWANCE OF A NEW AND REFINED METHOD OF USE PATENT FOR LUPKYNIS® IN THE TREATMENT OF LUPUS NEPHRITIS FROM THE USPTO

Yahoo | January 24, 2023

Investors ignore increasing losses at Aurinia Pharmaceuticals (NASDAQ:AUPH) as stock jumps 21% this past week

When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...

Yahoo | January 16, 2023

Why Shares of Aurinia Pharmaceuticals Soared This Week

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were up by 79.6% this week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. The biopharmaceutical company, which specializes in treating autoimmune disorders, closed last Friday at $4.32, then rose to as high as $7.80 in the early afternoon this Friday. Aurinia reported full-year revenue of $134 million, up 112% over 2021.

Yahoo | January 6, 2023

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

VICTORIA, British Columbia, January 06, 2023--AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2022 NET REVENUE RESULTS

Yahoo | January 6, 2023

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

VICTORIA, British Columbia, January 04, 2023--AURINIA PHARMACEUTICALS TO PRESENT AT UPCOMING 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Yahoo | January 4, 2023

Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 4, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VICTORIA, British Columbia, January 03, 2023--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | January 3, 2023

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

VICTORIA, British Columbia, January 03, 2023--AURINIA ANNOUNCES LUPKYNIS® (voclosporin) PATENT CHALLENGE SETTLEMENT REACHED WITH SUN PHARMACEUTICALS

Yahoo | January 3, 2023

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

VICTORIA, British Columbia, November 30, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus

Yahoo | November 30, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7387 seconds.